Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 17/20 | 0.55 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.55 |
| ▸ | BRD4 | O60885 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | BRD1 | O95696 | 10/20 | 0.34 |
| ▸ | BRPF3 | Q9ULD4 | 5/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198329 | 0.85 | BRPF1 (0.55) | BRPF1BRD9BRD4CA12CA9 | |
| Hydrochloric Acid SCHEMBL7218030 | 0.72 | BRPF1 (0.92) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL248619 | 0.71 | BRPF1 (1.00) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL29967380 | 0.71 | BRPF1 (1.00) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL552070 | 0.71 | PIK3CD (0.43) | BRPF1BRD4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL17673679 | 0.71 | MEN1 (0.34) | KDM4E | |
| Hydrochloric Acid SCHEMBL1236989 | 0.69 | BRPF1 (0.96) | BRPF1BRD9BRD4CA12CA9 | |
| Hydrochloric Acid SCHEMBL30419636 | 0.69 | BRPF1 (0.96) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL686703 | 0.69 | CYP2A6 (0.40) | PIK3CBKDM4ENQO2 | |
| SCHEMBL18230486 | 0.69 | HTR2A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| CN-101228131-B | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD | 2013-01-09 | — | — | CN | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7910751-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| CN-101228131-A | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | BRPF1 2857/4885BRD9 893/4885BRD4 1103/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | BRPF1 2857/4885BRD9 893/4885BRD4 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.